Cash flow from operations was $234 million, capital expenditures were $30 million, and free cash flow was $204 million.
Greater China revenue was $63 million, slightly ahead of expectations but down $12 million year-over-year due to export restrictions.
Illumina repurchased approximately 4.5 million shares for $380 million during Q2, with about $800 million authorization remaining.
In Q2 2025, Illumina reported revenue of approximately $1.06 billion, down about 3% year-over-year on both constant currency and reported basis.
Non-GAAP gross margin was 69.4%, up 200 basis points quarter-over-quarter and stable year-over-year, aided by favorable product mix and operating excellence initiatives.
Non-GAAP operating expenses were $484 million, down 6% year-over-year reflecting cost discipline and prioritization of growth investments.
Non-GAAP operating margin was 23.8%, up 160 basis points year-over-year, with non-GAAP EPS of $1.19, a 9% increase year-over-year and above guidance.
Sequencing consumables revenue was approximately flat year-over-year at $740 million and up about 6% sequentially.
Sequencing instruments revenue was $96 million, down approximately 18% year-over-year due to constrained budgets in research customers.
Dafinchi